Related Experiment Videos
The Björk-Shiley tilting disc valve in the tricuspid position. 10-year experience
Insights
The Björk-Shiley pyrolytic carbon disc prosthesis demonstrated satisfactory outcomes in tricuspid valve replacement over ten years. This study found no instances of thromboembolism, valve thrombosis, or endocarditis in twelve patients, indicating good prosthesis safety.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
Background:
- Tricuspid valve disease necessitates surgical intervention.
- Prosthetic valve choice impacts patient outcomes.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of the Björk-Shiley pyrolytic carbon disc prosthesis for tricuspid valve replacement.
Main Methods:
- Retrospective analysis of hospital records.
- Review of ten-year follow-up data for twelve patients.
Main Results:
- One operative mortality due to tracheo-oesophageal fistula.
- Four late deaths from various causes, including unknown.
- Absence of thromboembolic events, valve thrombosis, or subacute infective endocarditis.
Conclusions:
- The Björk-Shiley pyrolytic carbon disc prosthesis is a safe and effective option for tricuspid valve replacement.
- The prosthesis showed a favorable safety profile with no major thrombotic or infectious complications.
Abstract:
Ten-year experience of tricuspid valve replacement with the Björk-Shiley pyrolytic carbon disc is reported. Of the twelve patients, one died in association with the operation, due to tracheo-oesophageal fistula. There were four late deaths, two from unknown causes, one during re-replacement of mitral valve and one from carcinoma of the urinary bladder. No patient had thromboembolism, valve thrombosis or subacute infective endocarditis. From the analysis of the hospital records and follow-up data it is concluded that the Björk-Shiley pyrolytic carbon disc prosthesis is a satisfactory substitute for the tricuspid valve.